孟鲁司特钠与布地奈德联合治疗喘息性支气管肺炎患儿的临床效果

Clinical Effects of Montelukast Sodium and Budesonide in Children with Wheezy Bronchopneumonia

目的:探讨孟鲁司特钠与布地奈德联合治疗喘息性支气管肺炎患儿的临床效果。方法:选择2021年4月—2023年6月黔西南州中医院收治的90例喘息性支气管肺炎患儿,按随机数字表法将90例患儿分为两组。对照组用布地奈德治疗,观察组用布地奈德联合孟鲁司特钠治疗,均治疗14 d。比较两组临床疗效、症状消失时间、血清炎症因子、血常规及不良反应。结果:观察组临床总有效率为95.56%(43/45),高于对照组的80.00%(36/45),差异有统计学意义(P<0.05)。观察组发热时间为(2.03±0.42)d,咳嗽时间为(4.25±1.36)d,哮鸣音消失时间为(2.25±1.13)d,湿啰音消失时间为(4.81±1.27)d,喘息消失时间为(3.84±0.92)d,均早于对照组的(3.05±0.52)、(6.31±1.62)、(5.61±1.72)、(7.89±2.59)、(6.22±1.26)d,差异均有统计学意义(P<0.05)。治疗后,观察组超敏C反应蛋白(hs-CRP)为(6.42±0.85)mg/L,白细胞计数(WBC)为(6.75±2.24)×10^(9)/L,中性粒细胞百分比(NE%)为(46.12±3.29)%,均低于对照组的(7.04±0.92)mg/L、(10.62±2.51)×10^(9)/L、(54.58±3.87)%,差异均有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:孟鲁司特钠与布地奈德联合治疗喘息性支气管肺炎患儿效果明显,可有效促进患儿症状好转,降低血清炎症因子水平,安全可靠。

Objective:To investigate the clinical efficacy of Montelukast Sodium and Budesonide in the treatment of wheezy bronchopneumonia.Method:A total of 90 children with wheezing bronchopneumonia admitted to Qianxinan Traditional Chinese Medicine Hospital from April 2021 to June 2023 were selected,according to the random number table method,90 children were divided into two groups with 45 cases each.The control group was treated with Budesonide and the observation group was treated with Montelukast Sodium combined with Budesonide,both for 14 d.The clinical efficacy,time of symptom disappearance,serum inflammatory factors,blood routine and adverse effects were compared in two groups.Result:The clinical efficacy of the observation group was 95.56%(43/45),which was higher than 80.00%(36/45)of the control group,the difference was statistically significant(P<0.05).In the observation group,the fever time was(2.03±0.42)d,cough time was(4.25±1.36)d,wheezing sound disappeared time was(2.25±1.13)d,wet rales disappeared time was(4.81±1.27)d,wheezing disappeared time was(3.84±0.92)d,which were earlier than(3.05±0.52),(6.31±1.62),(5.61±1.72),(7.89±2.59),(6.22±1.26)d in the control group(P<0.05).After treatment,in the observation group,the hypersensitive C reactive protein(hs-CRP)was(6.42±0.85)mg/L,the white blood cell count(WBC)was(6.75±2.24)×10^(9)/L,and the percentage of neutrophils(NE%)was(46.12±3.29)%,which were lower than(7.04±0.92)mg/L,(10.62±2.51)×10^(9)/L,(54.58±3.87)%of the control group,the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combination of Montelukast Sodium and Budesonide has obvious effect in treating children with wheezy bronchopneumonia,which can effectively promote the improvement of symptoms,reduce the level of serum inflammatory factors,and is safe and reliable.